Tag:

Bristol-Myers Squibb

Latest Headlines

Latest Headlines

The skinny on earnings: Cost cuts boost Merck, Bristol-Myers, Forest as FX hits Sanofi

While many drugmakers were marveling over Pfizer's big bid for AstraZeneca or speculating about which megadeal might come next, a few big pharma companies rolled out their first-quarter earnings reports. Let's give them their due. Besides, we can't be all deals, all the time. Here are the highlights--or, given the almost-uniform slide in sales, the lowlights.

UPDATED: Bristol-Myers heads to FDA with nivolumab, but not fast enough

Bristol-Myers isn't wasting any time in pushing its closely watched immuno-oncology drug nivolumab to the FDA.

Bristol-Myers targets neurodegenerative diseases in $725M deal to buy iPierian

About 7 months after splitting her company into two biotechs, CEO Nancy Stagliano has sold iPierian and its preclinical foray against neurodegenerative diseases--including Alzheimer's--to Bristol-Myers Squibb for $175 million down and up to $550 million in milestones.

Bristol-Myers deepens CMO deal with Samsung

Piggybacking off an earlier deal, Bristol-Myers Squibb has signed another manufacturing agreement with South Korean giant Samsung. 

BMS extends deal with Samsung as its pipeline percolates with more biologics

With a host of biologic products in its pipeline, Bristol-Myers Squibb sees the need for more capacity for making large-molecule drugs and has decided to build on a relationship it already has with South Korea's Samsung BioLogics.

Bristol-Myers extends manufacturing pact with Samsung

Bristol-Myers Squibb hooked up with South Korea's Samsung last year when it wanted someone to handle manufacturing overseas for its hot-selling melanoma drug Yervoy. But with more promising biologics in its pipeline, the New York-based drugmaker has decided to deepen its commitment.

Which therapies top Thomson Reuters' list of new drugs to watch this year?

The industry analysts at Thomson Reuters put their heads together to tap the biggest new blockbusters in the making this year and surprised no one by capping the list with Gilead's Sovaldi.

BMS sues ex-account manager, claiming she took PD-1 marketing secrets to Merck agency

No company likes to lose an integral part of its marketing team--and especially not to a competitor. Bristol-Myers Squibb is taking the news particularly personally, suing a former account manager and her new agency for misappropriation of trade secrets.

Bristol-Myers enlists DKSH to push its drugs in Asia

Bristol-Myers Squibb is re-upping with market-access outfit DKSH to dial up its commercialization efforts in Asia, extending a deal signed in 2010.

Bristol-Myers jockeys for promising position in hep C drug race

Three days after Bristol-Myers Squibb filed for FDA approval of the NS5A drug daclatasvir combined with asunaprevir, an NS3 protease inhibitor, the biotech company has turned over some of the Phase III cards it will be playing for an approval in markets around the world.